Regulation of the tumour suppressor PP2A by oncogenic tyrosine kinases

Roberts, Kathryn

Title: Regulation of the tumour suppressor PP2A by oncogenic tyrosine kinases
Creator: Roberts, Kathryn
Relation: University of Newcastle Research Higher Degree Thesis
Resource Type: thesis
Date: 2010
Description: Research Doctorate - Doctor of Philosophy (PhD)
Description: Reversible protein phosphorylation plays a central role in the regulation of intracellular signalling, and is controlled by the opposing activities of protein kinases and phosphatases. Deregulation of these mechanisms can result in increased proliferation and enhanced survival, which is a hallmark feature of malignant transformation. For example, over 90% of chronic myeloid leukaemia (CML) patients express the BCR/ABL oncoprotein, which exhibits unrestrained tyrosine kinase activity. In addition, activating mutations within the receptor tyrosine kinase, c-KIT, contribute to the pathogenesis of gastrointestinal stromal tumours (GIST), systemic mastocytosis, acute myeloid leukaemia (AML), testicular seminoma and melanoma. The advent of small molecule tyrosine kinase inhibitors, such as imatinib, has revolutionised the treatment of malignancies driven by these oncogenic kinases. However, a proportion of patients are either unresponsive or develop resistance, and as such, relapse and disease progression is a major clinical problem. In order to improve the treatment outcome for these patients, a greater understanding of the signalling pathways regulated downstream of BCR/ABL and c-KIT is required. The data presented in this thesis indicates that oncogenic BCR/ABL and mutant c-KIT both require inhibition of the tumour suppressor, protein phosphatase 2A (PP2A), to induce tumourigenesis. PP2A is a large family of serine/threonine phosphatases that provide the fine control on signalling pathways by governing the rate and duration of phosphorylation. The heterotrimeric PP2A enzyme is comprised of a structural subunit (PP2A Aα and Aβ), a catalytic subunit (PP2Acα and cβ) and a regulatory subunit, which consists of three unrelated families: B55 (α, β, γ, δ), B56 (α, β, γ, δ, ε) and B" (PR72/130 / PR70/48). Binding of the regulatory subunit to the core PP2A AC dimer directs both the substrate specificity and cellular localisation of the enzyme. The combinatorial assembly of these individual components permits the formation of distinct complexes which have been implicated in numerous cellular functions such as proliferation, survival and mitosis. In particular, important roles for PP2A in various aspects of malignant transformation are beginning to emerge. Recent work demonstrates that PP2A is functionally inactivated by BCR/ABL in myeloid progenitor cells. Using the mouse myeloid progenitor cell line, FDC-P1, these observations were confirmed in the current study. Detailed investigation into the underlying mechanisms have demonstrated for the first time that active BCR/ABL increases the expression of the PP2A structural and certain regulatory subunits. This alters the PP2A holoenzyme composition and results in the abundance of complexes containing B55α and B56α. Consequently, B56γ, a known tumour suppressive subunit, appears to be simultaneously displaced. To investigate which subunits are functionally important for BCR/ABL-mediated leukaemogenesis, individual PP2A subunits were targeted with shRNA sequences in WT BCR/ABL FDC-P1 cells. Subsequent evaluation identified B56α as a key player which facilitates the leukaemic phenotype. In accordance with an increase in PP2A activity, knockdown of B56α significantly inhibited the cellular growth and reduced the clonogenic potential of BCR/ABL⁺ myeloid progenitors. Furthermore, suppression of the B56δ subunit in WT BCR/ABL FDC-P1 cells appears to delay progression through the cell cycle. Together, these findings provide new insights into the biology of PP2A and begin to define the precise mechanisms by which BCR/ABL induces leukaemogenesis via PP2A in CML. Investigation of the regulation of PP2A was also extended to the oncogenic tyrosine kinase, c-KIT. Using FDC-P1 cells expressing imatinib-sensitive (V560G) or –resistant (D816V) mutant c-KIT, this work demonstrates for the first time that constitutive activation of c-KIT impairs the activity of PP2A, and this is essential for tumourigenesis. Pharmacological reactivation of PP2A with FTY720 significantly reduced the proliferation, impaired the clonogenic potential and induced apoptosis of oncogenic c-KIT cells, whilst having no effect on empty vector controls or WT c-KIT cells stimulated with stem cell factor (SCF). These cytotoxic effects of FTY720 are mediated, in part, by the rapid dephosphorylation, and hence inactivation, of oncogenic c-KIT receptors. These promising in vitro findings were translated into an in vivo model, where the daily administration of FTY720 significantly delayed the growth of mutant c-KIT⁺ tumours. Furthermore, FTY720 markedly prevented the infiltration of D816V c-KIT tumour cells into secondary lymphoid organs, such as the spleen and bone marrow. As a result, the survival of FTY720-treated mice was significantly prolonged compared to saline-treated controls. Overall, this body of work greatly enhances our understanding of PP2A function and identifies the complex mechanisms of PP2A regulation by the oncogenic tyrosine kinases, BCR/ABL and c-KIT. Taken together, the data suggests that inhibition of PP2A may represent a general mechanism employed by constitutively active kinases to facilitate tumour growth. As such, this work supports the future application of PP2A-activating agents in a broad range of human malignancies.
Subject: PP2A; FTY720; c-KIT; BCR/ABL; tumour suppressor
Identifier: http://hdl.handle.net/1959.13/802947
Identifier: uon:6254
Language: eng
Full Text

Hits: 2030
Visitors: 2745
Downloads: 847

		Thumbnail	File	Description	Size	Format
View Details Download			ATTACHMENT01	Abstract	140 KB	Adobe Acrobat PDF	View Details Download
View Details Download			ATTACHMENT02	Thesis	5 MB	Adobe Acrobat PDF	View Details Download